Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2015 16:05 ET | Source: RestorGenex

RestorGenex and Diffusion Pharmaceuticals Announce Merger Agreement

--Proposed Merger Would Create an Oncology-Focused Biotechnology Company ----Combined Company Expects to Initiate Phase III Clinical Trial in GBM for Orphan Drug-Designated TSC in 2016--BUFFALO GROVE,...
November 12, 2015 16:15 ET | Source: RestorGenex

RestorGenex Reports Third Quarter 2015 Financial Results

BUFFALO GROVE, Ill., Nov. 12, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
October 06, 2015 07:00 ET | Source: RestorGenex

RestorGenex to Present at Two Upcoming Growth Conferences

BUFFALO GROVE, Ill., Oct. 6, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
September 03, 2015 06:30 ET | Source: RestorGenex

RestorGenex to Present at Rodman & Renshaw Global Investment Conference

BUFFALO GROVE, Ill., Sept. 3, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
August 12, 2015 06:30 ET | Source: RestorGenex

RestorGenex Reports Financial Results

BUFFALO GROVE, Ill., Aug. 12, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
July 14, 2015 06:30 ET | Source: RestorGenex

RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor

BUFFALO GROVE, Ill., July 14, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
June 23, 2015 06:30 ET | Source: RestorGenex

RestorGenex Announces Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor

BUFFALO GROVE, Ill. and ROME, June 23, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
June 19, 2015 06:30 ET | Source: RestorGenex

RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor

BUFFALO GROVE, Ill., June 19, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
June 18, 2015 06:30 ET | Source: RestorGenex

RestorGenex Announces Stockholder Approval of Reincorporation in Delaware

BUFFALO GROVE, Ill., June 18, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
June 16, 2015 06:30 ET | Source: RestorGenex

RestorGenex CEO Featured in Equities.com Interview

BUFFALO GROVE, Ill., June 16, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...